Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | Semaglutide tells your brain that you just ate a huge meal, making you feel completely full all day long. It also slows down your digestion so your blood sugar stays perfectly flat, leading to massive weight loss. | CagriSema is a super-team of two weight-loss signals. One tells your stomach to stay full, and the other tells your brain to stop craving sugar. Working together, they cause massive weight loss without feeling starved. |
Studied For | Type 2 diabetes managementChronic weight management / obesityCardiovascular risk reductionHbA1c loweringAppetite suppressionBody weight reductionNon-alcoholic fatty liver disease (NAFLD/MASH)Kidney disease in diabetes (SELECT trial)Obstructive sleep apneaAlzheimer's / neurodegeneration researchAddiction / substance use disorder researchCardiovascular outcomes improvementInsulin resistanceMetabolic syndromePre-diabetes preventionPolycystic ovary syndrome (PCOS) researchGLP-1 receptor agonist researchweight lossfat lossappetite suppressantincretinanti-obesitydiabetesblood sugar controlcardiovascular healthbinge eatingcraving reduction | Obesity / overweightType 2 diabetesDual-mechanism weight lossGLP-1 plus amylin dual therapyCardiometabolic diseaseHbA1c reductionAppetite suppression dual pathwayBody weight reductionMetabolic syndromeInsulin resistanceBlood sugar controlCaloric intake reduction researchCombination incretin amylin therapyCardiovascular risk reductionobesityappetite suppressionextreme weight lossmetabolic control |
Research Areas | MetabolicWeight Management & Fat Loss | MetabolicWeight Management & Fat Losshormonal |
Best Stacked With | l-carnitineb12lipo-cglutathionebac-water | l-carnitineb12bac-water |
Overview | ||
Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
Compound Class | GLP-1 receptor agonist; fatty-acid conjugated 31-amino-acid peptide analog of human GLP-1 | Fixed-ratio combination: long-acting amylin analog (cagrilintide) + GLP-1 receptor agonist (semaglutide) |
Molecular Target | GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay | Amylin/calcitonin receptors (cagrilintide) + GLP-1 receptor (semaglutide); dual satiety and glucose regulation |
Aliases / AKA | OzempicWegovyRybelsusNN9535Semaglutide peptideGLP-1 agonist semaglutide | CagriSemaCagriSema combinationCagrilintide semaglutideAM833 NN9535Amylin GLP-1 dual agonistDual obesity drug |
Parent Compound | Human GLP-1 | Cagrilintide and Semaglutide |
Molecular Weight | 4113.58 Da | combination |
Amino Acid Sequence | 31-aa GLP-1 analog (Aib2, C18 diacid) | cagrilintide + semaglutide |
CAS Number | 910463-68-2 | n/a |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | ||
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 5,205 Extensive | Not Listed |
Clinical Trials | 399399 Active | Not Listed |
Regulatory Status | FDA-approved: Ozempic (T2D, 2017); Rybelsus (oral T2D, 2019); Wegovy (obesity, 2021); Ozempic label expanded for CKD risk reduction in T2D (Jan 2025); Wegovy approved for MASH with moderate-to-advanced fibrosis (Aug 2025). Compounded salt forms (sodium/acetate) cautioned by FDA as not established safe/effective. | Investigational (Novo Nordisk); NDA filed with FDA Dec 18, 2025 (under FDA review in 2026); not yet approved. |
Evidence & Regulatory | ||
Half-Life | ~1 week | ~1 week (both components weekly SC) |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Strong human trials: about 15 percent weight loss at 68 weeks (STEP) and reduced major cardiovascular events (SELECT). FDA-approved. | Phase 3 REDEFINE 1 (2025, 68 weeks) reported about 22.7 percent mean body-weight reduction in obesity, exceeding either component alone. |
Side Effects Noted | Dose-dependent gastrointestinal effects; gallbladder disease and acute pancreatitis signals; hypoglycemia mainly with insulin or sulfonylureas. | Predominantly gastrointestinal, consistent with both component classes. |
Warnings | FDA boxed warning for thyroid C-cell tumors; contraindicated with personal or family medullary thyroid carcinoma or MEN 2. FDA cautions that compounded salt forms are not established as safe and effective. | Investigational with no approved indication. Inherits the GLP-1 class thyroid C-cell and pancreatitis considerations. Research use only. |
Pharmacology | ||
Form | lyophilized (research) or pen | lyophilized |
Diluent | bacteriostatic water | bacteriostatic or sterile water |
Storage Temp | refrigerate 2-8C pre-use | frozen/refrigerated, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Heat, freeze-thaw, and agitation sensitive. | See component profiles. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
